Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | CPI-613 |
Trade Name | |
Synonyms | CPI613|CPI 613|Devimistat |
Drug Descriptions |
Devimistat (CPI-613) is an inhibitor of pyruvate dehydrogenase (PDH) and alpha-ketogluterate (KGDH), resulting in blockade of mitochondrial respiration which may lead to apoptosis and death of cancer cells (PMID: 29437791, PMID: 28495639, PMID: 32789692, PMID: 31512500). |
DrugClasses | |
CAS Registry Number | 95809-78-2 |
NCIT ID | C80039 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bendamustine + CPI-613 | Bendamustine CPI-613 | 0 | 1 |
Cisplatin + CPI-613 + Gemcitabine | CPI-613 Cisplatin Gemcitabine | 0 | 1 |
CPI-613 | CPI-613 | 0 | 2 |
CPI-613 + Cytarabine + Mitoxantrone | CPI-613 Cytarabine Mitoxantrone | 0 | 1 |
CPI-613 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin | CPI-613 Fluorouracil Irinotecan Leucovorin Oxaliplatin | 0 | 3 |
CPI-613 + Hydroxychloroquine | CPI-613 Hydroxychloroquine | 0 | 2 |